Chezi Ganzel

20PUBLICATIONS
42CO-AUTHORS
Medical infection agents (incl. prions)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Dec 31, 2024
Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Avraham Frisch, Chezi Ganzel, Yishai Ofran

|Dec 25, 2024
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

Chezi Ganzel, Avraham Frisch, Ofir Wolach

|Dec 05, 2024
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.

Ofir Wolach, Itai Levi, Boaz Nachmias

|Jul 18, 2024
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

C Ganzel, Y Wang, K Roopcharan

|May 23, 2024
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.

Eitan Kugler, Inbar Cohen, Irina Amitai

|May 22, 2024
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

C Ganzel, Y Wang, K Roopcharan

Pageof 4

Frequent Collaborators

8 joint publications

Yishai Ofran

5 joint publications

Yael C Cohen

4 joint publications

Moshe Gatt

4 joint publications

Ofir Wolach